Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 19 publications
0
5
0
Order By: Relevance
“…Recent studies focused on comparing fixed- and variable-dose protocols in atraumatic bleedings. Overall, weight-dependent variable-dosage protocols were superior to fixed-dosage protocols ( 128 , 129 ), but door-to-needle time was shorter in fixed-dose protocols ( 129 ). When PCC is not available, FFP can be used as an alternative.…”
Section: Resultsmentioning
confidence: 91%
“…Recent studies focused on comparing fixed- and variable-dose protocols in atraumatic bleedings. Overall, weight-dependent variable-dosage protocols were superior to fixed-dosage protocols ( 128 , 129 ), but door-to-needle time was shorter in fixed-dose protocols ( 129 ). When PCC is not available, FFP can be used as an alternative.…”
Section: Resultsmentioning
confidence: 91%
“…Warfarin is used in clinical practice since 1941 and has been frequently used as an anticoagulation in atrial fibrillation, venous thromboembolism, mechanical heart valves, and a variety of various other clinical settings. In fact, warfarin is one of the most widely prescribed drugs in the industrialized world, 35 with multiple recent reports also confirming this statement 36-41 . Warfarin causes anticoagulation by inhibiting the vitamin K epoxy reductase—the enzyme which is necessary for posttranslational carboxylation of many coagulation factors including factors II, VII, IX, and X as well as protein C and protein S 42 .…”
Section: Perspectivesmentioning
confidence: 97%
“…In fact, warfarin is one of the most widely prescribed drugs in the industrialized world, 35 with multiple recent reports also confirming this statement. [36][37][38][39][40][41] Warfarin causes anticoagulation by inhibiting the vitamin K epoxy reductase-the enzyme which is necessary for posttranslational carboxylation of many coagulation factors including factors II, VII, IX, and X as well as protein C and protein S. 42 Bleeding caused by warfarin is one of the most important which is associated with high morbidity and mortality. 43 It is one of the most reported serious adverse events that were reported in the 1990 s and 2000 s to the US Food and Drug Administration.…”
Section: Perspectivesmentioning
confidence: 99%
“…Several studies comparing fixed and weight-based dosing have been conducted, with the majority being low to very low-quality evidence based upon their study design (Table 2). 24–27 Overall data suggest that using a fixed-dose of 1000 to 1500 units of PCC is safe and may be considered, whereas higher doses may be needed in certain populations, such as patient with severely elevated INRs upon admission, patients with ICrH, or in patients weighing more than 100 kg 10,24,28,29. A recent prospective, open-label, randomized controlled trial evaluated the safety and efficacy of a fixed dose of 1500 units (34 patients) versus weight-based (37 patients) 4F-PCC dosing regimen for warfarin reversal.…”
Section: Evidence For Pcc Use With Warfarinmentioning
confidence: 99%
“…Researchers found that weight-based dosing resulted in more patients achieving a goal INR of 1.5 or less (89.2% vs 61.8%; P = .01) when compared with fixed dosing. However, these results are limited as the study was stopped early due to enrollment issues, but this data raises concern regarding the efficacy of fixed dosing compared with weight-based dosing and also introduces concern that fixed-dosing regimens may not be effective in those with higher INR levels at baseline 28. Due to the overall low-quality evidence on this subject, additional randomized controlled trials must be conducted to determine whether the theoretical benefits of this strategy translate into clinical practice.…”
Section: Evidence For Pcc Use With Warfarinmentioning
confidence: 99%